利用人群水平有效性数据预测传染病结局的免疫保护并应用于COVID-19
本文提出一个通用统计模型,依据疫苗有效性估计与中和抗体水平等保护相关指标,校准并预测不同免疫暴露(疫苗与感染的数量、类型和毒株)对症状、住院、死亡及感染获得与突破感染传播等结局的保护强度,并考虑免疫衰减。模型应用于SARS-CoV-2,预测自然感染Delta与Omicron B.1.1.529变异株及BioNTech-Pfizer(BNT162b2)、Oxford-AstraZeneca(ChAdOx1)和第三剂mRNA加强针对Delta与Omicron结局的个体保护效力,并展示2021年末Omicron出现时快速更新推断新变异免疫原性与内在传播力的用例。
要点
- 模型校准免疫保护水平时同时利用人群水平数据(如疫苗有效性估计)和中和抗体水平作为保护相关指标。
- 模型预测症状、住院、死亡及感染获得与突破感染传播等结局的保护。
- 模型可随新变异流行病学数据快速更新,推断免疫原性与内在传播力。
核心结论
- 该通用模型能够利用人群水平有效性数据预测不同免疫暴露对多种传染病结局的保护强度,并考虑免疫衰减。
- 模型应用于SARS-CoV-2,可预测自然感染Delta与Omicron B.1.1.529变异株及BioNTech-Pfizer(BNT162b2)、Oxford-AstraZeneca(ChAdOx1)和第三剂mRNA加强针对Delta与Omicron结局的个体保护效力。
- 在2021年末Omicron出现时,模型可快速更新以推断新变异的关键免疫原性与内在传播力特征。
研究设计与样本
- 本文提出一个通用统计模型,用于预测不同免疫暴露对多种结局的保护强度并考虑免疫衰减。
- 模型校准免疫保护水平时利用人群水平数据(如疫苗有效性估计)和中和抗体水平作为保护相关指标。
- 模型应用于SARS-CoV-2,预测自然感染Delta与Omicron B.1.1.529变异株及BioNTech-Pfizer(BNT162b2)、Oxford-AstraZeneca(ChAdOx1)和第三剂mRNA加强针对Delta与Omicron结局的保护效力。
主要发现
- 模型预测的结局包括症状、住院、死亡、感染获得及突破感染传播。
- 模型应用于SARS-CoV-2,预测自然感染Delta与Omicron B.1.1.529变异株及BioNTech-Pfizer(BNT162b2)、Oxford-AstraZeneca(ChAdOx1)和第三剂mRNA加强针对Delta与Omicron结局的个体保护效力。
- 模型在2021年末Omicron出现时,可快速更新以推断新变异的关键免疫原性与内在传播力特征。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Quantifying the extent to which previous infections and vaccinations confer protection against future infection or disease outcomes is critical to managing the transmission and consequences of infectious diseases. We present a general statistical model for predicting the strength of protection conferred by different immunising exposures (numbers, types, and strains of both vaccines and infections), against multiple outcomes of interest, whilst accounting for immune waning. We predict immune protection against key clinical outcomes: developing symptoms, hospitalisation, and death. We also predict transmission-related outcomes: acquisition of infection and onward transmission in breakthrough infections. These enable quantification of the impact of immunity on population-level transmission dynamics. Our model calibrates the level of immune protection, drawing on both population-level data, such as vaccine effectiveness estimates, and neutralising antibody levels as a correlate of protection. This enables the model to learn realised immunity levels beyond those which can be predicted by antibody kinetics or other correlates alone. We demonstrate an application of the model for SARS-CoV-2, and predict the individual-level protective effectiveness conferred by natural infections with the Delta and the Omicron B.1.1.529 variants, and by the BioNTech-Pfizer (BNT162b2), Oxford-AstraZeneca (ChAdOx1), and 3rd-dose mRNA booster vaccines, against outcomes for both Delta and Omicron. We also demonstrate a use case of the model in late 2021 during the emergence of Omicron, showing how the model can be rapidly updated with emerging epidemiological data on multiple variants in the same population, to infer key immunogenicity and intrinsic transmissibility characteristics of the new variant, before the former can be more directly observed via vaccine effectiveness data. This model provided timely inference on rapidly evolving epidemic situations of significant concern during the early stages of the COVID-19 pandemic. The general nature of the model enables it to be used to support management of a range of infectious diseases.
引用
- Hao T, Ryan GE, Lydeamore MJ, et al. Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19. Vaccine. 2025. PMID: 40117726. doi:10.1016/j.vaccine.2025.126987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。